Isolation of imipenem-resistant Enterobacter species:: Emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes

被引:158
作者
Marchaim, Dror [1 ]
Navon-Venezia, Shiri [1 ]
Schwaber, Mitchell J. [1 ]
Carmeli, Yehuda [1 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Div Epidemiol, IL-64239 Tel Aviv, Israel
关键词
D O I
10.1128/AAC.01103-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The prevalence of isolation of imipenem-resistant Enterobacter (IRE) strains is rising, with potential serious consequences in terms of patients' outcomes and general care. The study objective was to define the various epidemiological aspects of the isolation of these strains in comparison to cases of isolation of imipenem-susceptible Enterobacter (ISE) strains. Molecular analysis of IRE strains included genotyping and defining the presence of carbapenemases. We conducted a matched retrospective case-control study of patients hospitalized from April 2003 to December 2006. Each IRE case was matched with an ISE case by age and source of isolation. A multivariate analysis using conditional logistic regression was performed to compare the two patient groups. There were 33 cases of IRE isolations during the study period. Twenty isolates were analyzed and found to belong to three distinct pulsotypes. Cell extracts of all of these isolates hydrolyzed imipenem. PCR and sequencing revealed that these isolates harbored a KPC-2 gene. In multivariate analysis, a high invasive-device score (P = 0.02) remained a predictor of IRE isolation. The mortality in the IRE group was 33%, compared to 9% among controls. Being an IRE case was significantly associated with increased mortality after controlling for confounders in a multivariate model (odds ratio, 8.3 +/- 8.6; 95% confidence interval, 1.07 to 64; P = 0.043). Resistance to imipenem due to bla(KPC-2) among Enterobacter isolates has occurred in several clones in Tel Aviv, affecting particularly patients with multiple invasive devices compared to ISE controls. IRE infections are associated with increased mortality. Enhanced measures to control the hospital spread of IRE are warranted.
引用
收藏
页码:1413 / 1418
页数:6
相关论文
共 35 条
  • [21] Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome
    Kang, CI
    Kim, SH
    Park, WB
    Lee, KD
    Kim, HB
    Kim, EC
    Oh, MD
    Choe, KW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) : 760 - 766
  • [22] Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.
    Kaye, KS
    Cosgrove, S
    Harris, A
    Eliopoulos, GM
    Carmeli, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2628 - 2630
  • [23] Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital
    Leavitt, Azita
    Navon-Venezia, Shiri
    Chmelnitsky, Inna
    Schwaber, Mitchell J.
    Carmeli, Yehuda
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) : 3026 - 3029
  • [24] IDENTIFICATION OF BETA-LACTAMASES BY ANALYTICAL ISOELECTRIC-FOCUSING - CORRELATION WITH BACTERIAL TAXONOMY
    MATTHEW, M
    HARRIS, AM
    [J]. JOURNAL OF GENERAL MICROBIOLOGY, 1976, 94 (MAY): : 55 - 67
  • [25] Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel
    Navon-Venezia, Shiri
    Chmelnitsky, Inna
    Leavitt, Azita
    Schwaber, Mitchell J.
    Schwartz, David
    Carmeli, Yehuda
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 3098 - 3101
  • [26] Emerging carbapenemases in Gram-negative aerobes
    Nordmann, P
    Poirel, L
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (06) : 321 - 331
  • [27] Pottumarthy S, 2003, EMERG INFECT DIS, V9, P999
  • [28] Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel
    Schlesinger, J
    Navon-Venezia, S
    Chmelnitskv, I
    Hammer-Münz, O
    Leavitt, A
    Gold, HS
    Schwaber, MJ
    Carmeli, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 1150 - 1156
  • [29] Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens
    Schwaber, MJ
    Cosgrove, SE
    Gold, HS
    Kaye, KS
    Carmeli, Y
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (01) : 94 - 99
  • [30] Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species
    Schwaber, MJ
    Graham, CS
    Sands, BE
    Gold, HS
    Carmeli, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) : 1882 - 1886